Clinical Trial Update: Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA) [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the effect of eplerenone on novel biomarkers of mineralocorticoid receptor activation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• eplerenone (eplerenone)

Snippet

Sponsor: University of Michigan | Conditions: Hypertension | Phase 4 | Status: WITHDRAWN